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Abstract
Posttraumatic epilepsy is a major source of disability following traumatic brain injury (TBI) and a common cause of
medically-intractable epilepsy. Previous attempts to prevent the development of posttraumatic epilepsy with treatments
administered immediately following TBI have failed. Recently, the mammalian target of rapamycin complex 1 (mTORC1)
pathway has been implicated in mechanisms of epileptogenesis and the mTORC1 inhibitor, rapamycin, has been proposed
to have antiepileptogenic effects in preventing some types of epilepsy. In this study, we have tested the hypothesis that
rapamycin has antiepileptogenic actions in preventing the development of posttraumatic epilepsy in an animal model of
TBI. A detailed characterization of posttraumatic epilepsy in the mouse controlled cortical impact model was first performed
using continuous video-EEG monitoring for 16 weeks following TBI. Controlled cortical impact injury caused immediate
hyperactivation of the mTORC1 pathway lasting at least one week, which was reversed by rapamycin treatment. Rapamycin
decreased neuronal degeneration and mossy fiber sprouting, although the effect on mossy fiber sprouting was reversible
after stopping rapamycin and did not directly correlate with inhibition of epileptogenesis. Most posttraumatic seizures
occurred greater than 10 weeks after TBI, and rapamycin treatment for one month after TBI decreased the seizure frequency
and rate of developing posttraumatic epilepsy during the entire 16 week monitoring session. These results suggest that
rapamycin may represent a rational treatment for preventing posttraumatic epilepsy in patients with TBI.
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Introduction
Traumatic brain injury (TBI) represents an enormous public
health problem. Posttraumatic epilepsy (PTE) is a common
sequela of TBI and cause of significant morbidity and mortality
in TBI patients [1,2]. Cognitive deficits are also a frequent and
burdensome consequence of TBI and may be exacerbated by
uncontrolled seizures and adverse effects of seizure medication.
The risk of PTE is elevated for more than a decade following TBI
[3], providing a potential window of opportunity to prevent the
neurological complications following TBI. However, therapeutic
attempts to prevent PTE have failed – while standard seizure
medications can suppress seizures immediate following head
trauma, none have been shown to alter the subsequent natural
history or long-term risks of developing PTE [4,5]. In order to best
help TBI patients, more effective therapeutic agents are needed
that don’t simply suppress seizures once they start, but actually
prevent the development of epilepsy in the first place. In fact, no
such antiepileptogenic therapies have been developed for prevent-
ing any type of epilepsy.
A main reason that previous attempts to prevent PTE have
failed is that current seizure medications primarily act on
molecular mechanisms that mediate the end-stage symptoms of
epilepsy, the seizures themselves. A more rational, effective
strategy for preventing epilepsy is to target the primary signaling
pathways that initially trigger the numerous downstream cellular
and molecular mechanisms mediating epileptogenesis. One
signaling pathway, the mammalian target of rapamycin complex1
(mTORC1) pathway, represents a logical candidate for such a
mechanism, because mTORC1 regulates multiple physiological
functions in the brain, such as regulation of synaptic plasticity and
ion channel expression, which may promote epileptogenesis under
pathological conditions [6,7]. Importantly, rapamycin, a drug that
is already utilized clinically for immunological and oncological
indications, can be employed to inhibit the mTORC1 pathway
and thus may represent an easily-testable therapy for preventing
PTE in people.
The mTORC1 pathway has been implicated in epileptogenesis
in animal models of some forms of genetic epilepsy. In particular,
mTORC1 is abnormally activated in animal models of the genetic
epilepsy, tuberous sclerosis complex (TSC), and rapamycin can
prevent development of epilepsy in these models [8–11]. The
mTORC1 pathway may also be involved in epileptogenesis in
models of acquired epilepsy following status epilepticus or hypoxia
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[12–14], but this is more controversial [15,16]. Finally, the
mTORC1 pathway is abnormally activated in animal models of
TBI and mTORC1 pathway inhibitors reduce corresponding
behavioral deficits [17–19]. However, the role of mTORC1 in
PTE is not known, which would be a subject of much higher
clinical impact and application. In this study, we have character-
ized PTE and mTORC1 activation in the mouse controlled
cortical impact (CCI) injury model in detail using continuous
video-EEG monitoring for 16 weeks and tested the effect of
rapamycin on the development of PTE in this model of TBI.
Materials and Methods
Ethics Statement
Care and use of animals were conducted according to an animal
protocol approved by the Washington University Animal Studies
Committee (IACUC #A-3381-01, Approval #2010-0235). All
efforts were made to minimize animal discomfort and reduce the
number of animals used.
Animals and Surgery
All experiments were performed in accordance with guidelines
approved by the Animal Studies Committee at Washington
University School of Medicine. Male CD-1 mice (Harlan
Laboratories) of eight weeks of age were used in this study. Mice
were randomly assigned to experimental groups (control, sham-
operated, vehicle-treated TBI, rapamycin-treated TBI). The mice
had free access to food and water in a controlled environment.
The mice received a single left lateral CCI with an electromagnetic
CCI device allowing precisely-controlled cortical injuries, as
previously described [20]. Briefly, mice were anesthetized with
isoflurane and placed in a digital stereotaxic frame (David Kopf
Instruments), with an electric drill (Foredom) mounted on the right
stereotaxic arm and an impact device mounted on the left
stereotaxic arm at an angle of 15u from vertical (Fig. 1A). Rectal
temperature was maintained at 37uC with a warming pad and
feedback controller (Cell Microcontrols). A craniotomy was
performed over the left fronto-parietal cortex using a 5 mm
trephine (Meisinger) attached to the drill without damage to the
underlying dura. A 3 mm impact tip was positioned over the
center of the craniotomy site 3.0 mm anterior to lambda and
2.7 mm to the left of midline. The zero depth position was
determined by aligning the tip of the impact device in the down
position with the surface of the dura. The tip was then raised to the
cocked position, and the depth of injury was set by lowering the
impact tip 2 mm using the stereotaxic arm. CCI was triggered
using a Matlab-based computer controller. An impact injury was
delivered to compress the cortex to a depth of 2.0 mm at a velocity
of 5 m/s and 100 ms duration. After the injury, bleeding was
controlled with irrigation. The skull was then dried, and a 6-mm-
diameter plastic disc was glued with Vetbond (3 M) to the skull to
cover the craniotomy defect and prevent infection. The skin was
closed with nylon sutures and triple antibiotic ointment was
applied. The mice were returned to their home cages when fully
recovered from anesthesia. For the sham group, the same
procedures were applied except for the CCI injury itself. For
video-EEG studies, a subset of mice also had epidural EEG screw
electrodes implanted as described below.
Chemicals
Rapamycin (LC Labs) was initially dissolved in 100% ethanol
(30 mg/ml), stored at 220uC, and diluted (1:10) in a vehicle
solution containing 5% Tween 80, 5% PEG 400 (low-molecular-
weight grade of polyethylene glycol), and 4% ethanol immediately
before injection, as described previously [8]. Rapamycin (6 mg/
kg/d, i.p) or vehicle solution was injected 1 hour after TBI and
continued once daily for up to 4 weeks. All other chemicals were
obtained from Sigma unless indicated otherwise.
Western Blot Analysis
Mice were sacrificed at various time points (1 h, 3 h, 6 h, 24 h,
3 d, 1 wk, 2 wk, 3 wk) after CCI or sham surgery. The effects of
rapamycin versus vehicle were also tested at 6 hr, 3 d, 4 wk, and
16 wk after CCI. The ratio of phospho-S6 (P-S6, Ser240/244) to
S6 expression was primarily utilized as a measure of mTORC1
activation, using standard western blotting methods as described
previously [8]. In brief, protein extracts from neocortex and
hippocampi were separated by SDSPAGE and transferred to
nitrocellulose membranes. After blocking with 5% skim milk, the
membranes were incubated with rabbit anti-P-S6 antibody
(Ser240/244, 1:1000; Cell Signaling Technology), followed by
peroxidase-conjugated secondary antibody. After the signals were
visualized with ECL reagent (Pierce), the membranes were
reprobed and incubated with the rabbit anti-S6 antibody
(1:1000; Cell Signaling Technology). For comparison, additional
Western studies were similarly done to calculate the ratio of P-
4EBP1 (Ser65, 1:1000; Cell Signaling Technology) to 4EBP1
(1:1000) and P-STAT3 (Tyr705, 1:1000; Cell Signaling Technol-
ogy) to STAT3 (1:2000). Signals were quantitatively analyzed
using NIH ImageJ software.
Neuronal Degeneration Assays
Rapamycin- and vehicle-treated mice were sacrificed for
histological analysis of neuronal degeneration by Fluoro-Jade B
staining, 3 days after CCI. The mice were anesthetized with
isoflurane and transcardially perfused with PBS, followed by 4%
paraformaldehyde. The brains were then removed immediately
and postfixed with 4% paraformaldehyde overnight at 4uC. After
dehydrating in 30% sucrose for at least 24 h, the brains were
sectioned coronally at a thickness of 50 mm with a vibratome.
Three sections selected from a one-in-six series were collected
from each animal at the same level of hippocampus, starting at
2.8 mm posterior to bregma for Fluoro-Jade B staining.
Fluoro-Jade B (FJB) staining was performed as described
previously [12]. In brief, the sections were mounted on gelatin-
coated slides and dried at room temperature. After rehydration in
100% ethanol (EtOH) (5 min), 70% EtOH (2 min), and distilled
water (dH2O) (2 min), the sections were oxidized in 0.06%
potassium permanganate for 10 min, washed with dH2O, and
then immersed in 0.0004% FJB solution for 20 min in the dark.
Then the slides were washed in dH2O, air dried, cleared, and
coverslipped. A Zeiss LSM PASCAL confocal microscope with a
106/0.3 numerical aperture (NA) objective was used to acquire
images (9206920 mm fields) within CA1, CA3, and dentate (DG)
hilus at a similar location in different animals. The number of FJB
staining cells per image field in the hippocampal CA1, CA3, and
hilus were counted in each of the three sections per animal by an
examiner blinded to experimental conditions.
Mossy Fiber Sprouting Assay
Rapamycin- and vehicle-treated mice were sacrificed for
histological analysis of mossy fiber sprouting by Timm staining,
5 weeks and 16 weeks after CCI, as described previously [12]. The
mice were anesthetized and transcardially perfused with 0.9%
sodium chloride, 0.37% sodium sulfide sulfide solution and with
4% formaldehyde. The brains were then removed immediately
and postfixed with 4% paraformaldehyde overnight at 4uC. After
dehydrating in 30% sucrose for at least 24 h, the brains were
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sectioned coronally at a thickness of 50 mm with a vibratome.
One-in-six series of sections were mounted on slides, dried, and
developed for 60–80 min in 120 ml of 50% gum arabic, 20 ml of
2 M citrate buffer, 60 ml of 0.5 M hydroquinone, and 1 ml of
19% silver nitrate until the molecular layer in the DG was clearly
recognized. The sections were then photographed with a
Nanozoomer imager (Hamamatsu, Japan). Mossy fiber sprouting
was assessed according to previous methods [21]: 0, no granules
between the tip and crests of the dentate gyrus; 1, sparse granules
in the supragranular region in a patchy distribution between the
tip and crests of the dentate gyrus; 2, more numerous granules in
the supragranular region in a continuous distribution between the
tip and crests of the dentate gyrus; 3, prominent granules in the
supragranular region in a continuous pattern between the tip and
crests, with occasional patches of confluent granules between the
tip and crests; 4, prominent granules in the supragranular region
that form a confluent dense laminar band between the tip and
crests; and 5, a confluent dense laminar band of granules in the
supragranular region that extends into the inner molecular layer.
The Timm scores of individual sections were assigned by an
investigator blinded to the experimental conditions and were
averaged for each animal.
Video-EEG Recordings
Rapamycin- and vehicle-treated mice were monitored for
seizures after CCI by continuous video-EEG recording. For
surgical implantation of epidural electrodes, the mice were
anesthetized with 2% isoflurane. After CCI, bilateral anterior
and posterior epidural cortical screw electrodes (1.60 mm bregma,
1.80 mm lateral and 21.0 mm bregma, 4.8 mm lateral) and
ground (210 mm bregma, 1.0 mm lateral) electrodes were
implanted in the skull (Fig. 1B), and secured with dental cement
(Parkell). Mice were monitored continuously for 16 weeks after
CCI with a digital video-EEG acquisition system (PowerLab, AD
Instruments). All EEG data were reviewed by two trained
observers in a blinded fashion, and video recordings were analyzed
as needed to confirm behavioral correlates of electrographic
seizures and to rule out artifacts. Electrographic seizures were
clearly identifiable as discrete epochs of repetitive spike discharges,
starting as low amplitude high frequency discharges and evolving
into higher amplitude bursts, which lasted at least 10 s. In
addition, interictal spikes were identified and defined as fast
(,200 ms) epileptiform waveforms that had a stereotypic triphasic
morphology and were at least twice the amplitude of the
background activity. Acute symptomatic seizures occurred in
some mice during the first week (always the first 24 hours) after
CCI and were not counted as PTE. In contrast, PTE was defined
as any seizures occurring at least 1 week after CCI. Latency to first
seizure of PTE and seizure duration of all seizures was calculated.
Seizure frequency of PTE was calculated as the number of seizures
occurring during the time from the first seizure of PTE to the end
of the monitoring period (16 weeks after CCI).
Statistics
All statistical analysis was performed using GraphPad Prism
(GraphPad Software). Quantitative differences between groups
were analyzed by Student’s t test when comparing two groups, by
one-way ANOVA with Tukey’s multiple comparisons post hoc
tests when comparing more than two groups, or by repeated
measures two-way ANOVA when comparing multiple treatment
Figure 1. Controlled cortical impact (CCI) injury model in mice. (A) Impactor tip of an electromagnetic CCI device. (B) Schematic diagram of
sites of craniotomy, cortical injury, and EEG electrode placements. (C) Cresyl violet-stained coronal section documenting typical 2 mm CCI injury,
which leads to damage through the depth of the neocortex but leaves the underlying hippocampus grossly intact. *cortical injury site.
doi:10.1371/journal.pone.0064078.g001
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variables (e.g. sham vs. TBI, vehicle vs. rapamycin) over time.
Comparable non-parametric tests were used when data did not fit
a normal distribution. Fisher’s Exact Test and Mantel-Cox log-
rank tests were used to compare the incidence and survival analysis
of PTE between rapamycin- and vehicle-treated TBI mice.
Quantitative data are expressed as mean 6 SEM. Statistical
significance was defined as p,0.05.
Results
Rapamycin Inhibits Hyperactivation of the mTORC1
Pathway caused by CCI Injury
CCI was applied to the neocortex of 8 week old CD-1 mice at a
depth of 2.0 mm, which typically leads to damage through the
depth of the neocortex but leaves the underlying hippocampus
grossly intact (Fig. 1C). mTORC1 pathway activity, as reflected by
the ratio of phosphorylated S6 (P-S6, Ser240/244) to total S6
expression, was measured at various time intervals following CCI
injury. Compared with sham-operated mice, CCI injury caused
hyperactivation of the mTORC1 pathway in both neocortex and
hippocampus (Fig. 2). P-S6 expression started to increase within
3 hrs and peaked within 6 hrs after injury. Then, mTORC1
activity started to decrease within 24 hrs after CCI, but remained
elevated for at least one week, returning to normal levels by 2
weeks after injury. Rapamycin treatment, initiated one hour after
CCI and continued daily at 6 mg/kg inhibited the CCI-induced
increase in mTORC1 activity (Fig. 3A,B). Sustained daily
treatment with rapamycin for 4 weeks continued to suppress
mTORC1 activity as long as treatment was sustained (Fig. 3C,D),
but after rapamycin was stopped, mTORC1 activity subsequently
recovered to control levels (Fig. 3E,F).
To partially address the specificity of rapamycin’s effect for the
mTORC1 pathway in the CCI model, the expression of another
downstream mTORC1 target (4EBP1) and a non-mTORC1-
mediated phosphorylation pathway (JAK-STAT) was similarly
assessed following CCI and with rapamycin treatment. Similar to
P-S6, P-4EBP1 was significantly elevated at 3 days following CCI
and was inhibited by rapamycin (Fig. 4A). In contrast, while P-
STAT3 was also elevated following CCI consistent with recent
findings in another TBI model [22], rapamycin had no significant
effect on this increased P-STAT3 expression (Fig. 4B).
Rapamycin Decreases Neuronal Degeneration and Mossy
Fiber Sprouting following CCI Injury
Neuronal death and mossy fiber sprouting are pathological
abnormalities that might contribute to epileptogenesis and other
neurological sequelae following TBI, as well as other types of
epilepsy. In addition to the direct cortical tissue loss from the CCI
injury, neuronal death was detected in the hippocampus within 3
days after CCI. Treatment with rapamycin, starting one hour
following CCI and continuing daily at 6 mg/kg/d for up to 3 days,
decreased the amount of neuronal degeneration in hippocampus,
as reflected by Fluoro-Jade B staining (Fig. 5). Similarly, mossy
fiber sprouting in dentate gyrus occurred after CCI and rapamycin
treatment decreased this mossy fiber sprouting, as reflected by
Timm staining (Fig. 6A–D). However, mossy fiber sprouting
started to recur after rapamycin treatment was stopped (Fig. 6E–
H).
Continuous Video-EEG Monitoring of PTE in the Mouse
CCI Injury Model
A couple of previous studies have documented PTE in the
mouse CCI model [23,24], but none have utilized continuous
video-EEG monitoring for extended periods. In this study, we
performed video-EEG monitoring continuously for 16 weeks
following CCI injury. In vehicle-treated TBI mice, 31% (5 of 16)
of mice had acute symptomatic seizures in the first week after CCI,
all within the first 24 hours after CCI. 50% (8 of 16) of vehicle-
treated TBI mice developed PTE, defined as spontaneous seizures
occurring at least one week after CCI. All seizures had a
stereotypical EEG pattern involving an initial low amplitude,
high frequency spike discharge evolving into higher amplitude,
repetitive bursts of spikes, with average duration of 35.562.8 sec
(Fig. 7A). Behaviorally seizures were characterized primarily by
behavioral arrest, clonic movements of the limbs, rearing and
falling over (Movie S1). All (5 of 5) the vehicle-treated TBI mice
that had acute symptomatic seizures developed PTE, whereas only
27% (3 of 11) of mice that did not have acute symptomatic seizures
developed PTE, indicating that acute symptomatic seizures are a
reliable marker of future epilepsy (p,0.05 by Fisher’s Exact test).
In the vehicle-treated TBI mice that developed PTE (n = 8), the
latency to first seizure was 82.3610.2 days, with a range of 13–108
days. One mouse, which appeared to be an outlier, started having
seizures in the second week (13 day latency), had relatively
frequent seizures for three weeks, and then stopped having seizures
for the remainder of the 16 week monitoring period. Otherwise,
the remaining mice had a relatively consistent latency to first
seizure (92.164.5 days, range 76–108 days). Overall, the seizure
frequency of mice with PTE (n= 8) was low, averaging 0.5560.16
seizures/day, as measured from the day of the first seizure to the
last day of the monitoring period. Seizures tended to cluster in a
random pattern, with all mice having some seizure-free periods of
at least 3 days and most having intervening seizure-free periods of
at least one week. Interictal epileptiform spike discharges were
relatively rare and tended to be seen on the days of seizure clusters
(Fig. 7B).
Rapamycin Decreases Seizures Frequency following CCI
Injury
To test whether rapamycin has beneficial effects on PTE in the
TBI mice, rapamycin treatment (6 mg/kg, i.p.) was initiated 1
hour after CCI injury and was continued daily for 4 weeks. The
incidence, latency, frequency, and duration of seizures were
compared between rapamycin-treated versus vehicle-treated TBI
mice following CCI (Table 1). A similar percentage of rapamycin-
treated TBI mice had acute symptomatic seizures in the first week
following CCI (38%, 6 of 16) as vehicle-treated TBI mice (31%, 5
of 16; p.0.05). However, rapamycin-treated mice had a
significantly lower rate of developing PTE over the 16 week
period following CCI injury compared to vehicle-treated TBI mice
(Fig. 7C; p,0.05, Mantel-Cox log-rank test). Overall, 13% (2 or
16) of rapamycin-treated mice ultimately developed PTE com-
pared to 50% (8 of 16) vehicle-treated mice (p,0.05 by Fisher’s
Exact test). The only two rapamycin-treated mice with PTE had a
latency to first seizure of 91.063.5 days and a seizure frequency of
0.1860.04 seizures/day, as measured from the day of the first
seizure to the last day of the monitoring period. When comparing
the frequency of seizures of all mice in both groups (including the
mice that did not develop PTE: seizure frequency = 0 seizures/
day), the rapamycin-treated mice had a significantly lower seizure
frequency (0.0260.02 seizures/day, n= 16) compared with
vehicle-treated mice (0.2760.11 seizures/day, n = 16; p,0.05,
Mann-Whitney U-test). Seizure semiology and duration were
similar in vehicle- and rapamycin-treated mice (p.0.05). Rapa-
mycin had no significant effect on body weight (data not shown).
No mortality, infections, or overt behavioral changes were
observed in either rapamycin or vehicle-treated mice.
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Discussion
In this study, we have shown that the mTORC1 pathway is
abnormally activated following CCI injury in mice and that
rapamycin attenuates the neuropathological consequences of TBI,
including neuronal death and mossy fiber sprouting. Furthermore,
we have performed a detailed characterization of PTE in the CCI
model and shown that rapamycin decreased the seizure frequency
and rate of development of PTE following CCI injury. Overall,
this study suggests that rapamycin may have antiepileptogenic
actions in this animal model of TBI.
Characterization of PTE in the CCI Injury Model of PTE
Independent of the analysis of rapamycin’s effects, this study
provides a detailed video-EEG evaluation of PTE continuously for
16 weeks following CCI injury. Acute seizures within the first few
hours in CCI or related TBI models have been well-documented
in previous studies [25,26]. Other studies have also demonstrated
PTE (i.e., spontaneous seizures more than a week after TBI) in the
CCI model, but the characteristics of PTE and the monitoring
techniques have varied [23,24,27,28]. In our study, we used
continuous video-EEG monitoring for several months following
CCI to try and obtain a thorough assessment of incidence, latency,
and seizure frequency of PTE during this time period. We
documented PTE in 50% of vehicle-treated mice within 16 weeks
of CCI. By comparison, Hunt et al. [23] reported seizures in
,35% of mice recorded by video only during eleven 1–2 hour
recording sessions between 42 and 71 days after CCI. Given the
relatively limited amount of monitoring and the lack of use of
EEG, the reported incidence of PTE from this previous study is
likely an underestimate and thus may be even greater than our
study. Furthermore, while a precise latency to PTE could not be
measured with intermittent monitoring, the documentation of
seizures between 42–71 days after CCI in the previous study
represents an earlier time than the recorded latency to first seizure
in the majority of mice in our study (76–108 days, with the
exception of one mouse at 13 days). As both the Hunt et al. study
and our study used CD-1 mice, the most likely source of any
differences between the two studies is the severity of the CCI
injury. While the Hunt et al. study actually used a lower depth of
penetration (1.0 mm), we have utilized an electromagnetic
controlled CCI device that improves accuracy and minimizes
overshoot, thus potentially providing a more consistent injury [20].
Figure 2. The mTORC1 pathway is abnormally activated following TBI. mTORC1 activation, as reflected by the ratio of P-S6 to total S6
expression, was significantly increased in both hippocampus and neocortex, whereas sham-operated animals showed no such increase. This increase
in P-S6 expression started at 3 hr, peaked at 6 hr (A, B) and then decreased within 1 wk, returning to baseline by 2 wk (C, D) after CCI. There is no
significant difference between naı¨ve mice (Ctrl) versus sham-operated mice. *p,0.05 vs. Sham at the same time point by two-way repeated measures
ANOVA. n = 8 mice per group in A,B and n= 6 mice per group in C,D.
doi:10.1371/journal.pone.0064078.g002
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Another study utilized video-EEG monitoring, with two 2-week
monitoring periods at 6 months and a third 2-week monitoring
session at 9 months after CCI in mice [24]. In this previous study,
,10% of mice had PTE at 6 months after CCI, with no evidence
of progression at 9 months; in fact, no mice had documented
seizures at 9 months after CCI. Compared to our study, the lower
prevalence of PTE in the previous study could simply be related to
the less amount of total monitoring time. Alternatively, since our
study stopped monitoring at ,4 months after CCI, combining the
time line of these two studies may suggest that seizure frequency
actually lessens over time in the CCI model. Furthermore, the
Bolkvadze and Pitkanen study [24] used C57-BL6 mice, which
may be more seizure-resistant compared with CD-1 mice.
In addition to allowing an accurate measure of incidence and
latency of PTE, use of continuous video-EEG monitoring in our
study also provided a detailed documentation of the frequency and
temporal pattern of seizures. Overall, the seizure frequency was
relatively low, consistent with other models of PTE [29], but less
than most status epilepticus-induced epilepsy models [30]. In
addition, an irregular or cluster pattern of seizures was frequently
seen, with consecutive days with seizures often interrupted by
seizure-free periods of a week or longer. These findings reinforce
the importance of continuous video-EEG monitoring to minimize
Figure 3. Rapamycin blocks mTORC1 activation induced by TBI. (A, B) Rapamycin treatment, initiated one hour after CCI injury and
continued daily at 6 mg/kg, inhibited mTORC1 activation at both 6 hr and 3 d following CCI, as reflected by the P-S6/S6 ratio. (C, D) Daily rapamycin
treatment for 4 weeks continued to inhibit mTOR activity. (E, F) After rapamycin was stopped, mTOR activity returned to control levels. *p,0.05 vs.
Ctrl+Veh; #p,0.05 vs. TBI+Veh at the same time point by two-way repeated measures ANOVA. n = 6 mice per group.
doi:10.1371/journal.pone.0064078.g003
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inaccuracies in seizure assessments related to the infrequency or
clustering of seizures. However, due to practical issues of time and
equipment availability for long-term monitoring, one potential
limitation of our study is the cessation of monitoring at 4 months.
It is possible that the incidence of PTE would have been higher if
monitoring was extended longer. Some studies in the fluid
percussion injury (FPI) rat model of TBI indicate that the
cumulative percentage of rats with PTE continues to increase
between 4 and 12 months of age [29], although other studies in the
FPI model indicate a maximal yield within 2 months [31]. Again,
in the CCI mouse model, one previous study found no evidence of
progression, but rather a decrease, in seizures between 6 and 9
months [24]. Although very laborious, the most complete
characterization of PTE in the CCI model would involve
continuous video-EEG monitoring for up to 12 months after CCI.
Antiepileptogenic Effects of mTORC1 Inhibition against
PTE in the CCI Injury Model
The role of the mTORC1 pathway in epileptogenesis and the
potential utility of mTORC1 inhibitors as antiepileptogenic
treatments has received increasing attention recently [6,7]. This
possibility has been most extensively investigated in the disease,
tuberous sclerosis complex (TSC), which represents one of the
most common genetic causes of epilepsy and is associated with
abnormal activation of the mTORC1 pathway [32]. Initiated at
an early age, rapamycin or related mTORC1 inhibitors can
prevent the development of epilepsy and many of the associated
pathological, cellular, and molecular brain abnormalities that
contribute to epileptogenesis in multiple different mouse models of
TSC [8–11]. An mTORC1 inhibitor has already been approved
for treating brain tumors that also occur in TSC patients and is
currently being investigated in clinical trials as treatments for
intractable seizures in TSC [33], although actual antiepileptogenic
Figure 4. Rapamycin inhibits increased P-4EBP1, but not P-STAT3, expression induced by TBI. For comparison with P-S6, the
phosphorylation of another downstream mTORC1 target (4EBP1) and a non-mTORC1 mediated phosphorylation pathway (JAK-STAT) was assessed
following CCI. (A) P-4EBP1 was elevated following CCI injury and was inhibited by rapamycin. (B) In contrast, P-STAT3 was increased after CCI, but was
not inhibited by rapamycin. *p,0.05 vs. Ctrl+Veh; #p,0.05 vs. TBI+Veh at the same time point by two-way repeated measures ANOVA. n = 6 mice
per group.
doi:10.1371/journal.pone.0064078.g004
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trials to prevent epilepsy have not yet been attempted. Besides
TSC, there is some evidence from animal models that mTORC1
could be involved in epileptogenesis and that rapamycin has
antiepileptogenic actions in acquired epilepsies following brain
injury. For example, in animal models of epilepsy following status
epilepticus (from kainate or electrical stimulation) or neonatal
hypoxia, treatment with rapamycin during or after the initial
injurious trigger attenuates the subsequent development of
epilepsy, as well as pathological changes, such as mossy fiber
sprouting [12–14]. Rapamycin may also acutely decrease existing
seizures in other animal models [34–39], although has also been
reported to have no effect on epilepsy in some cases [15,16].
Figure 5. Rapamycin reduces neuronal degeneration in hippocampus following TBI. Representative sections of Fluoro-Jade B staining in
different regions of hippocampus of control mice (Ctrl, A–C), vehicle-treated TBI mice (TBI+Veh, D–F) and rapamycin-treated TBI mice (TBI+Rap, G–I)
three days after CCI are shown. Abundant Fluoro-Jade B positive neurons are seen in vehicle-treated TBI mice in CA1, CA3 and DG, but to a lesser
degree in rapamycin-treated TBI mice. Quantitative analysis showed a significant decrease in Fluoro-Jade B positive cells in rapamycin-treated
compared to vehicle-treated TBI mice (J–L). *p,0.05 by one-way ANOVA, n = 6 mice per group.
doi:10.1371/journal.pone.0064078.g005
Figure 6. Rapamycin transiently reduces mossy fiber sprouting following TBI. (A–D) Timm staining shows mossy fiber sprouting from
control mice (Ctrl+Veh, A), and vehicle-treated TBI mice (TBI+Veh, B) and rapamycin-treated TBI mice (TBI+Rap, C) five weeks after CCI. Panels A1, B1
and C1 are higher magnification of boxed regions in panels A, B and C, respectively. Quantitative analysis demonstrates a significant increase in Timm
score in vehicle-treated TBI mice compared to control mice and a significant decrease in Timm score in rapamycin-treated compared to vehicle-
treated TBI mice (D). (E–H) At sixteen weeks after CCI (12 weeks after rapamycin was stopped), Timm score in rapamycin-treated TBI mice increased
back to similar levels of vehicle-treated TBI mice. *p,0.05 by one-way ANOVA, n= 6 mice per group.
doi:10.1371/journal.pone.0064078.g006
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Despite the accumulating data on mTORC1 involvement in
epileptogenesis in a variety of types of epilepsy, it is surprising that
the effects of rapamycin on animal models of PTE have not been
previously reported, especially given the high clinical impact of
human PTE and the feasibility of a preventative approach
following TBI. Our study confirms previous reports that the
mTORC1 pathway is abnormally activated following TBI [17,19].
More importantly, this study provides evidence that the mTORC1
pathway may be involved in epileptogenesis following TBI and
that rapamycin has antiepileptogenic actions. As a caveat, it
Figure 7. Rapamycin attenuates development of posttraumatic epilepsy in the CCI model. Representative EEG tracings of seizures (A) and
interictal epileptiform abnormalities (B). (C) Rapamycin treatment significantly decreased the development of PTE following TBI (*p,0.05 by Mantel-
Cox log-rank test).
doi:10.1371/journal.pone.0064078.g007
Table 1. Effect of Rapamycin on Posttraumatic Epilepsy (PTE) in the CCI Model.
Group/Treatment # (%) of Mice with PTE Latency to First Seizure Seizure Frequency (seizures/d) Seizure Duration (s)
TBI+Vehicle (n = 16) 8 (50%) 82.3610.2 0.2760.11 35.562.8
TBI+Rapamycin (n = 16) 2 (13%)* 91.063.5 0.0260.02** 37.6612.6
Vehicle- and rapamycin-treated mice with TBI were compared in the percentage of mice developing PTE, latency to first seizure, seizure frequency, and seizure duration.
Rapamycin caused a significant decrease in the percentage of mice developing PTE (monitored for 16 weeks following CCI) and seizure frequency, but had no effect on
latency to first seizure or seizure duration.
*p = 0.027 by one-sided Fisher’s Exact test,
**p,0.05 by Mann-Whitney test.
doi:10.1371/journal.pone.0064078.t001
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should be recognized that rapamycin, like most drugs, may have
other, off-target effects, including inhibition of other kinases. Thus,
in the absence of more specific molecular or genetic manipula-
tions, it is difficult to absolutely rule out the possibility that other
mTORC1-independent mechanisms may mediate some of the
effects of rapamycin observed in this study. Our results showing an
effect of rapamycin on downstream mTORC1 targets, S6 and
4EBP1, but not on the non-mTORC1 phosphorylation pathway
JAK-STAT, supports some degree of specificity for mTORC1, but
cannot eliminate a potential effect of rapamycin on other kinase
pathways. Future studies involving mTOR or S6 knockout mice
could more directly address whether the effects of rapamycin on
PTE are specifically mediated by the mTORC1 pathway.
Compared to the effects of rapamycin documented in other
epilepsy models, the effects of rapamycin in the present study are
remarkable in that they persisted for at least 16 weeks, despite
discontinuation of the drug at 4 weeks after TBI. Previous studies
in other models have often depended on continued rapamycin
treatment to maintain effectiveness [8,9,14]. This is perhaps not
surprising in the previous work in genetic models of epilepsy, such
as in TSC knockout mice, in which mTORC1 activity can
reactivate after rapamycin is stopped due to the underlying genetic
dysregulation. In contrast, the present results in the TBI models
suggests that rapamycin treatment exclusively during the limited
time in which mTORC1 activity is abnormally elevated (first few
weeks after TBI) is sufficient to prevent activation of downstream
mechanisms of epileptogenesis, and therefore continued treatment
beyond the period of abnormal mTORC1 activity is not
necessary.
Despite the evidence from the current study that mTORC1
inhibitors may have antiepileptogenic actions against PTE in the
CCI model, the cellular and molecular mechanisms downstream
from mTORC1 that mediate these effects are not known. For
decades, mossy fiber sprouting has been hypothesized to be
mediate epileptogenesis in the popular kainate and pilocarpine
status epilepticus models of brain injury and acquired limbic
epilepsy, but this has remained controversial. Mossy fiber
sprouting can be inhibited by rapamycin in status epilepticus
models, but will recur when rapamycin is stopped and does not
appear to correlate with antiepileptogenic effects of mTORC1
inhibition [15]. Similarly, in the present study, mossy fiber
sprouting following CCI injury was suppressed by rapamycin
during the four week treatment period, but then recurred after
discontinuation of rapamycin. Since the effect of rapamycin on
seizures persisted after discontinuation, this suggests that sustained
inhibition of mossy fiber sprouting is not necessary for blocking
epileptogenesis, at least for the period of time monitored in this
study. Neuronal death, which was also decreased by rapamycin, is
another candidate for mediating effects on epileptogenesis.
Furthermore, neurogenesis, inflammation, and altered expression
of ion channels and other proteins involved in neuronal
excitability, could also affect epileptogenesis and be modulated
by rapamycin. However, as the critical mechanisms mediating
epileptogenesis in traumatic and status epilepticus-induced brain
injury models are still not established, future investigations will be
needed to pinpoint the downstream effectors of rapamycin in these
models.
The clinical relevance and therapeutic applications of the
present study are significant. The medical, social, and economic
impact of TBI and PTE is enormous [40]. The often long latent
period between TBI and subsequent development of PTE offers a
window of opportunity to administer a potential antiepileptogenic
treatment. In fact, well-designed, controlled clinical trials have
been conducted attempting to prevent PTE with standard seizure
medications, although the results have been negative [4,5,41]. The
pre-clinical data from the present study provides initial ‘‘proof-of-
principle’’, which could eventually lead to testing rapamycin for
antiepileptic effects in preventing PTE in clinical trials. Such trials
could involve TBI patients with high risk of developing epilepsy,
such as those with penetrating brain injuries, substantial intrapa-
renchymal hemorrhage, and possibly ApoE4 genotype [42].
However, our present study has a number of limitations and
several other critical preclinical questions will need to be addressed
first. These include a more detailed analysis of the safety and side
effects of rapamycin in the setting of TBI, the time window after
injury at which rapamycin is effective (one hour after injury is
clinically feasible only for a small subset of patients), the brain
levels of rapamycin required to obtain the antiepileptogenic effect,
and the effect of rapamycin on overall outcomes. Finally,
confirmation of the efficacy of rapamycin in pre-clinical studies
with larger numbers and other models of TBI would further
support initiation of an antiepileptogenic drug trial for PTE.
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